LYNPARZA (AstraZeneca)

← Back to Medical Devices, Pharma & Biotech BS Detector Get Business Strategy

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech

Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…

Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…

Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…

Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

(https://lynparza.com) 📸 Data Snapshot: May 31, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)

HOMEPAGE LYNPARZA® (olaparib) – Official Patient Website (https://lynparza.com)

Title

LYNPARZA® (olaparib) – Official Patient Website

Meta

Find out about LYNPARZA® (olaparib), a targeted treatment for certain types of cancer. See Important Safety Information, downloadable resources and more.

H1 Discover if LYNPARZA, a targeted treatment, is right for you

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Advanced or Recurrent Ovarian Cancer – LYNPARZA® (olaparib) (https://lynparza.com/ovarian-cancer/home.html)

Title

Advanced or Recurrent Ovarian Cancer – LYNPARZA® (olaparib)

Meta

Learn more about how LYNPARZA® (olaparib) is used for certain types of advanced or recurrent ovarian cancer.

H1 LYNPARZA for advanced or recurrent ovarian cancer

H2 Is LYNPARZA right for you?

H2 Maintenance therapy may be an option

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H3 LYNPARZA as a first-line maintenance therapy may be:

H3 LYNPARZA as a maintenance therapy may be appropriate if your ovarian cancer:

H3 Talk to your doctor about whether maintenance therapy with LYNPARZA is right for you

NAV_HEADER_REPEATED_FOOTER Patient Support – LYNPARZA® (olaparib) (https://lynparza.com/patient-support.html)

Title

Patient Support – LYNPARZA® (olaparib)

Meta

Access resources designed to support you during your treatment with LYNPARZA® (olaparib), including information about the AstraZeneca Access 360™ program.

H1 Patient support

H2 Financial support

H2 Additional support

H2 Talking to your doctor

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H3 AstraZeneca strives to make LYNPARZA affordable by aiming to provide a $0 co-pay for all eligible patients

H3 Helping you access the care you need

H3 To learn more about the Access 360 program

H3 What is LYNPARZA?

H3 Genetic testing

NAV_HEADER_REPEATED MyLYNPARZA Support Program – LYNPARZA® (olaparib) (https://lynparza.com/patient-support/my-lynparza-support-program.html)

Title

MyLYNPARZA Support Program – LYNPARZA® (olaparib)

Meta

Join the MyLYNPARZA Support Program to receive information for you and your loved ones throughout your treatment. Consider signing up for MyLYNPARZA by completing this form.

H1 Education and support are available through MyLYNPARZA

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

H2 WHAT IS LYNPARZA?

H2 IMPORTANT SAFETY INFORMATION

📝 The Narrative — clean text per page (Info Density · Semantic Coherence)

HOMEPAGE (https://lynparza.com) LYNPARZA® (olaparib) – Official Patient Website

[H1] Discover if LYNPARZA, a targeted treatment, is right for you

Select a cancer type below
Advanced or recurrent ovarian cancer Metastatic prostate cancer Early or metastatic breast cancer Metastatic pancreatic cancer

Not real patients.

Discover LYNPARZA—an oral, non-chemotherapy medication that may give you and your doctor a different option in the treatment of certain types of cancer.
Together with your doctor, you can discuss the possibilities and decide on the unique treatment plan to best help you.

More
[H2] WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD)-positive, which is identified by a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
that has come back and has a certain type of inherited or acquired abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy

human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene:

with a high risk of recurrence. LYNPARZA is given after surgery (treatment after surgery is called adjuvant therapy). You should have received chemotherapy medicines before or after surgery to remove the tumor
that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive breast cancer, you should have either already received hormonal therapy or hormone therapy is not the right treatment for you

pancreatic cancer (adenocarcinoma) that has spread to other parts of the body and has a certain type of abnormal inherited BRCA gene. LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of your first treatment with platinum-based chemotherapy

metastatic castration-resistant prostate cancer (mCRPC):

with a certain type of inherited or acquired abnormal homologous recombination repair (HRR) genes. LYNPARZA is used when the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone and has progressed after treatment with other anti-cancer medicines called enzalutamide or abiraterone
with a certain type of abnormal inherited or acquired BRCA gene, and the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. LYNPARZA is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine prednisone or prednisolone

[H2] IMPORTANT SAFETY INFORMATION

What is the most important information I should know about LYNPARZA?
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:

[H2] WHAT IS LYNPARZA?

Read More
LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD)-positive, which is identified by a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
that has come back and has a certain type of inherited or acquired abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy

human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene:

with a high risk of recurrence. LYNPARZA is given after surgery (treatment after surgery is called adjuvant therapy). You should have received chemotherapy medicines before or after surgery to remove the tumor
that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive breast cancer, you should have either already received hormonal therapy or hormone therapy is not the right treatment for you

pancreatic cancer (adenocarcinoma) that has spread to other parts of the body and has a certain type of abnormal inherited BRCA gene. LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of your first treatment with platinum-based chemotherapy

metastatic castration-resistant prostate cancer (mCRPC):

with a certain type of inherited or acquired abnormal homologous recombination repair (HRR) genes. LYNPARZA is used when the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone and has progressed after treatment with other anti-cancer medicines called enzalutamide or abiraterone
with a certain type of abnormal inherited or acquired BRCA gene, and the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. LYNPARZA is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine prednisone or prednisolone

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.
It is not known if LYNPARZA is safe and effective in children.

[H2] IMPORTANT SAFETY INFORMATION

Read More
What is the most important information I should know about LYNPARZA?
LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:

before treatment with LYNPARZA
every month during treatment with LYNPARZA
weekly if you have low blood cell counts that last a long time

Lung problems (pneumonitis). LYNPARZA can cause serious lung problems that can lead to death. Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms.
Blood clots (venous thromboembolism [VTE]). Some people may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lungs (pulmonary embolism [PE]), which may be severe or lead to death. Tell your healthcare provider right away if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.
Liver problems, including Drug-Induced Liver Injury (DILI): People taking LYNPARZA may develop liver problems which may be severe and can lead to death. Your healthcare provider should do blood tests before and during your treatment with LYNPARZA. Tell your healthcare provider right away if you notice discomfort on the right side of your stomach-area (abdominal), dark or “tea-colored” urine, or yellowing of your skin or the whites of your eyes (jaundice).
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LYNPARZA if you get certain side effects.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:

have lung or breathing problems
have kidney problems
are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
Females who are able to become pregnant:
your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
you should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you
tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA

Males with female partners who are pregnant or able to become pregnant:
you should use effective birth control (contraception) during treatment with LYNPARZA and for 3 months after the last dose of LYNPARZA
do not donate sperm during treatment with LYNPARZA and for 3 months after your last dose

are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?

Take LYNPARZA tablets exactly as your healthcare provider tells you
Your healthcare provider will decide how long you stay on treatment
Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to
Take LYNPARZA by mouth 2 times a day with or without food
Each dose should be taken about 12 hours apart
Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
If you are taking LYNPARZA for early breast cancer and you have hormone receptor-positive disease, you should continue to take hormonal therapy during your treatment with LYNPARZA
If you are taking LYNPARZA for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with LYNPARZA unless you have had a surgery to remove both of your testicles (surgical castration) to lower the amount of testosterone in your body
If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?
Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
LYNPARZA may cause serious side effects (see "What is the most important information I should know about LYNPARZA?").
Nausea or vomiting is common during treatment with LYNPARZA. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms.
The most common side effects of LYNPARZA when used alone are:

tiredness or weakness
low red blood cell counts
diarrhea
loss of appetite
headache
changes in the way food tastes
cough
low white blood cell counts
shortness of breath
dizziness
indigestion or heartburn
low platelet counts

The most common side effects of LYNPARZA when used in combination with bevacizumab are:

tiredness or weakness
low red blood cell counts
diarrhea
low white blood cell counts
urinary tract infection
headache

The most common side effects of LYNPARZA when used in combination with abiraterone and prednisone or prednisolone are:

low red blood cell counts
tiredness or weakness
diarrhea
loss of appetite
low white blood cell counts
dizziness
stomach-area (abdominal) pain

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects. You may report side effects related to AstraZeneca products(Opens in new window)
[IMG: Visit AstraZeneca.com to Report Side Effects]
.
Please see complete Prescribing Information, including Medication Guide.

[H2] WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used as

15000 chars

SUB-PAGE (https://lynparza.com/ovarian-cancer/home.html) Advanced or Recurrent Ovarian Cancer – LYNPARZA® (olaparib)

[H1] LYNPARZA for advanced or recurrent ovarian cancer

Talk to your doctor about LYNPARZA for certain types of advanced or recurrent ovarian cancer.
Learn about Nicole and her journey with advanced ovarian cancer and LYNPARZA >

A real patient.

LYNPARZA is used as a maintenance therapy and can be taken alone or in combination with the medicine bevacizumab. Maintenance therapy is a treatment used after initial therapy has ended. It can help extend the time without cancer growing or returning.
[H2] Is LYNPARZA right for you?

[H3] LYNPARZA as a first-line maintenance therapy may be:

Taken in combination with bevacizumab if your advanced ovarian cancer has tested positive for HRD (homologous recombination deficiency) and has responded to your first treatment with platinum-based chemotherapy

OR

Taken alone if your advanced ovarian cancer has tested positive for a BRCA mutation and has responded to your first treatment with platinum-based chemotherapy

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

See LYNPARZA results for advanced ovarian cancer
Find out more about the side effects of LYNPARZA

[H3] LYNPARZA as a maintenance therapy may be appropriate if your ovarian cancer:

Has come back (also known as recurrent ovarian cancer)
Has responded to the most recent treatment with platinum-based chemotherapy
Has tested positive for a BRCA mutation

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

See LYNPARZA results for recurrent ovarian cancer
Find out more about the side effects of LYNPARZA

[H2] Maintenance therapy may be an option

Ovarian cancer is a disease in which cells in the ovaries multiply and grow abnormally. This type of cancer is prone to recurrence, which means it can become resistant to chemotherapy or return after surgery and/or chemotherapy, even if you have no evidence of detectable cancer cells in your body.
After chemotherapy, you can expect to be followed closely with exams, tests, and/or scans. If you are eligible, you may also be prescribed maintenance therapy.
Maintenance therapy may help keep your advanced or recurrent ovarian cancer from growing or returning after you have had a response to platinum-based chemotherapy.
Without maintenance therapy, advanced ovarian cancer may return in about 70% of women within 3 years after their first treatment course, even in those who have no evidence of disease.
Maintenance therapy may also help preserve the progress you’ve seen on chemotherapy.

7 out of 10 women may have recurrence

[H3] Talk to your doctor about whether maintenance therapy with LYNPARZA is right for you

More
[H2] WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD)-positive, which is identified by a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
that has come back and has a certain type of inherited or acquired abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy

human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene:

with a high risk of recurrence. LYNPARZA is given after surgery (treatment after surgery is called adjuvant therapy). You should have received chemotherapy medicines before or after surgery to remove the tumor
that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive breast cancer, you should have either already received hormonal therapy or hormone therapy is not the right treatment for you

pancreatic cancer (adenocarcinoma) that has spread to other parts of the body and has a certain type of abnormal inherited BRCA gene. LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of your first treatment with platinum-based chemotherapy

metastatic castration-resistant prostate cancer (mCRPC):

with a certain type of inherited or acquired abnormal homologous recombination repair (HRR) genes. LYNPARZA is used when the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone and has progressed after treatment with other anti-cancer medicines called enzalutamide or abiraterone
with a certain type of abnormal inherited or acquired BRCA gene, and the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. LYNPARZA is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine prednisone or prednisolone

[H2] IMPORTANT SAFETY INFORMATION

What is the most important information I should know about LYNPARZA?
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:

[H2] WHAT IS LYNPARZA?

Read More
LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD)-positive, which is identified by a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
that has come back and has a certain type of inherited or acquired abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy

human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene:

with a high risk of recurrence. LYNPARZA is given after surgery (treatment after surgery is called adjuvant therapy). You should have received chemotherapy medicines before or after surgery to remove the tumor
that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive breast cancer, you should have either already received hormonal therapy or hormone therapy is not the right treatment for you

pancreatic cancer (adenocarcinoma) that has spread to other parts of the body and has a certain type of abnormal inherited BRCA gene. LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of your first treatment with platinum-based chemotherapy

metastatic castration-resistant prostate cancer (mCRPC):

with a certain type of inherited or acquired abnormal homologous recombination repair (HRR) genes. LYNPARZA is used when the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone and has progressed after treatment with other anti-cancer medicines called enzalutamide or abiraterone
with a certain type of abnormal inherited or acquired BRCA gene, and the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. LYNPARZA is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine prednisone or prednisolone

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.
It is not known if LYNPARZA is safe and effective in children.

[H2] IMPORTANT SAFETY INFORMATION

Read More
What is the most important information I should know about LYNPARZA?
LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:

before treatment with LYNPARZA
every month during treatment with LYNPARZA
weekly if you have low blood cell counts that last a long time

Lung problems (pneumonitis). LYNPARZA can cause serious lung problems that can lead to death. Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms.
Blood clots (venous thromboembolism [VTE]). Some people may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lungs (pulmonary embolism [PE]), which may be severe or lead to death. Tell your healthcare provider right away if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.
Liver problems, including Drug-Induced Liver Injury (DILI): People taking LYNPARZA may develop liver problems which may be severe and can lead to death. Your healthcare provider should do blood tests before and during your treatment with LYNPARZA. Tell your healthcare provider right away if you notice discomfort on the right side of your stomach-area (abdominal), dark or “tea-colored” urine, or yellowing of your skin or the whites of your eyes (jaundice).
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LYNPARZA if you get certain side effects.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:

have lung or breathing problems
have kidney problems
are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
Females who are able to become pregnant:
your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
you should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you
tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA

Males with female partners who are pregnant or able to become pregnant:
you should use effective birth control (contraception) during treatment with LYNPARZA and for 3 months after the last dose of LYNPARZA
do not donate sperm during treatment with LYNPARZA and for 3 months after your last dose

are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?

Take LYNPARZA tablets exactly as your healthcare provider tells you
Your healthcare provider will decide how long you stay on treatment
Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to
Take LYNPARZA by mouth 2 times a day with or without food
Each dose should be taken about 12 hours apart
Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
If you are taking LYNPARZA for early breast cancer and you have hormone receptor-positive disease, you should continue to take hormonal therapy during your treatment with LYNPARZA
If you are taking LYNPARZA for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with LYNPARZA unless you have had a surgery to remove both of your testicles (surgical castration) to lower the amount of testosterone in your body
If you miss a dose of LYNPAR

15000 chars

SUB-PAGE (https://lynparza.com/patient-support.html) Patient Support – LYNPARZA® (olaparib)

[H1] Patient support

Access resources that are designed to guide and support you during your treatment with LYNPARZA.

Not a real doctor or patient.

[H2] Financial support

[IMG: Patients May Pay As Little as $0 per Month]

[H3] AstraZeneca strives to make LYNPARZA affordable by aiming to provide a $0 co-pay for all eligible patients

Eligible patients with commercial insurance may pay as little as $0 per month for LYNPARZA. There are no income requirements to participate in the program, however other restrictions may apply. For more information and eligibility requirements, visit AZPatientSupport.com.

[IMG: AstraZeneca Access 360™ Logo]

[H3] Helping you access the care you need

The AstraZeneca Access 360™ program* can help you get started with LYNPARZA.
[H3] To learn more about the Access 360 program

Please call
1-844-ASK-A360
(1-844-275-2360)
Monday–Friday
8 AM–6 PM ET
or visit www.MyAccess360.com
This description of the Access 360 program is for informational purposes only. Access 360 does not file claims or appeals on behalf of healthcare professionals or patients and makes no representation or guarantee concerning reimbursement or coverage for any service or item.
*Terms and conditions apply. See site for full eligibility and terms of use.

[H2] Additional support

Caring for your loved one—and yourself
Looking after your loved one on LYNPARZA takes time and a lot of energy. Find out why it’s really important to take care of yourself as well.
Learn about caregiver support

Support hotline
If you have any questions about LYNPARZA, speak to one of our specially trained nurses.
To speak with a nurse, call 1-800-770-8337.

Connect with others
Whether you’re a patient or caregiver, finding your own support network and connecting with others can help reduce stress, anxiety, and loneliness. Ask a nurse or social worker to help you find a support group or national organization.

[H2] Talking to your doctor

You should talk to your doctor as early as possible after your diagnosis about whether LYNPARZA is right for you. Here are a few questions that can help you make the most out of your time with your doctor.

[H3] What is LYNPARZA?

Is LYNPARZA right for me?
How is LYNPARZA different from chemotherapy?
Will taking LYNPARZA help me with my cancer?
What should I expect when taking LYNPARZA?

[H3] Genetic testing

Why is genetic testing important?
I’ve had a genetic test. Do I need another one?
Where and how can I get tested?

More
[H2] WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD)-positive, which is identified by a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
that has come back and has a certain type of inherited or acquired abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy

human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene:

with a high risk of recurrence. LYNPARZA is given after surgery (treatment after surgery is called adjuvant therapy). You should have received chemotherapy medicines before or after surgery to remove the tumor
that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive breast cancer, you should have either already received hormonal therapy or hormone therapy is not the right treatment for you

pancreatic cancer (adenocarcinoma) that has spread to other parts of the body and has a certain type of abnormal inherited BRCA gene. LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of your first treatment with platinum-based chemotherapy

metastatic castration-resistant prostate cancer (mCRPC):

with a certain type of inherited or acquired abnormal homologous recombination repair (HRR) genes. LYNPARZA is used when the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone and has progressed after treatment with other anti-cancer medicines called enzalutamide or abiraterone
with a certain type of abnormal inherited or acquired BRCA gene, and the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. LYNPARZA is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine prednisone or prednisolone

[H2] IMPORTANT SAFETY INFORMATION

What is the most important information I should know about LYNPARZA?
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:

[H2] WHAT IS LYNPARZA?

Read More
LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene:

metastatic castration-resistant prostate cancer (mCRPC):

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.
It is not known if LYNPARZA is safe and effective in children.

[H2] IMPORTANT SAFETY INFORMATION

Read More
What is the most important information I should know about LYNPARZA?
LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:

before treatment with LYNPARZA
every month during treatment with LYNPARZA
weekly if you have low blood cell counts that last a long time

Lung problems (pneumonitis). LYNPARZA can cause serious lung problems that can lead to death. Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms.
Blood clots (venous thromboembolism [VTE]). Some people may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lungs (pulmonary embolism [PE]), which may be severe or lead to death. Tell your healthcare provider right away if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.
Liver problems, including Drug-Induced Liver Injury (DILI): People taking LYNPARZA may develop liver problems which may be severe and can lead to death. Your healthcare provider should do blood tests before and during your treatment with LYNPARZA. Tell your healthcare provider right away if you notice discomfort on the right side of your stomach-area (abdominal), dark or “tea-colored” urine, or yellowing of your skin or the whites of your eyes (jaundice).
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LYNPARZA if you get certain side effects.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:

have lung or breathing problems
have kidney problems
are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
Females who are able to become pregnant:
your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
you should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you
tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA

Males with female partners who are pregnant or able to become pregnant:
you should use effective birth control (contraception) during treatment with LYNPARZA and for 3 months after the last dose of LYNPARZA
do not donate sperm during treatment with LYNPARZA and for 3 months after your last dose

are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?

Take LYNPARZA tablets exactly as your healthcare provider tells you
Your healthcare provider will decide how long you stay on treatment
Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to
Take LYNPARZA by mouth 2 times a day with or without food
Each dose should be taken about 12 hours apart
Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or d

15000 chars

SUB-PAGE (https://lynparza.com/patient-support/my-lynparza-support-program.html) MyLYNPARZA Support Program – LYNPARZA® (olaparib)

*Indicates required field

[IMG: MyLYNPARZA Support Program Logo]
[H1] Education and support are available through MyLYNPARZA

AstraZeneca developed this support program to be there for you and your loved ones during treatment with LYNPARZA. By signing up, you will receive advice and information about treatment including:

Email support
Useful tips
A treatment journal

*Indicates required field

[IMG: AstraZeneca Logo]

More
[H2] WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD)-positive, which is identified by a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
that has come back and has a certain type of inherited or acquired abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy

human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene:

with a high risk of recurrence. LYNPARZA is given after surgery (treatment after surgery is called adjuvant therapy). You should have received chemotherapy medicines before or after surgery to remove the tumor
that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive breast cancer, you should have either already received hormonal therapy or hormone therapy is not the right treatment for you

pancreatic cancer (adenocarcinoma) that has spread to other parts of the body and has a certain type of abnormal inherited BRCA gene. LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of your first treatment with platinum-based chemotherapy

metastatic castration-resistant prostate cancer (mCRPC):

with a certain type of inherited or acquired abnormal homologous recombination repair (HRR) genes. LYNPARZA is used when the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone and has progressed after treatment with other anti-cancer medicines called enzalutamide or abiraterone
with a certain type of abnormal inherited or acquired BRCA gene, and the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. LYNPARZA is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine prednisone or prednisolone

[H2] IMPORTANT SAFETY INFORMATION

What is the most important information I should know about LYNPARZA?
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:

[H2] WHAT IS LYNPARZA?

Read More
LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD)-positive, which is identified by a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
that has come back and has a certain type of inherited or acquired abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy

human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene:

with a high risk of recurrence. LYNPARZA is given after surgery (treatment after surgery is called adjuvant therapy). You should have received chemotherapy medicines before or after surgery to remove the tumor
that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive breast cancer, you should have either already received hormonal therapy or hormone therapy is not the right treatment for you

pancreatic cancer (adenocarcinoma) that has spread to other parts of the body and has a certain type of abnormal inherited BRCA gene. LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of your first treatment with platinum-based chemotherapy

metastatic castration-resistant prostate cancer (mCRPC):

with a certain type of inherited or acquired abnormal homologous recombination repair (HRR) genes. LYNPARZA is used when the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone and has progressed after treatment with other anti-cancer medicines called enzalutamide or abiraterone
with a certain type of abnormal inherited or acquired BRCA gene, and the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. LYNPARZA is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine prednisone or prednisolone

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.
It is not known if LYNPARZA is safe and effective in children.

[H2] IMPORTANT SAFETY INFORMATION

Read More
What is the most important information I should know about LYNPARZA?
LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:

before treatment with LYNPARZA
every month during treatment with LYNPARZA
weekly if you have low blood cell counts that last a long time

Lung problems (pneumonitis). LYNPARZA can cause serious lung problems that can lead to death. Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms.
Blood clots (venous thromboembolism [VTE]). Some people may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lungs (pulmonary embolism [PE]), which may be severe or lead to death. Tell your healthcare provider right away if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.
Liver problems, including Drug-Induced Liver Injury (DILI): People taking LYNPARZA may develop liver problems which may be severe and can lead to death. Your healthcare provider should do blood tests before and during your treatment with LYNPARZA. Tell your healthcare provider right away if you notice discomfort on the right side of your stomach-area (abdominal), dark or “tea-colored” urine, or yellowing of your skin or the whites of your eyes (jaundice).
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LYNPARZA if you get certain side effects.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:

have lung or breathing problems
have kidney problems
are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
Females who are able to become pregnant:
your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
you should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you
tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA

Males with female partners who are pregnant or able to become pregnant:
you should use effective birth control (contraception) during treatment with LYNPARZA and for 3 months after the last dose of LYNPARZA
do not donate sperm during treatment with LYNPARZA and for 3 months after your last dose

are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?

Take LYNPARZA tablets exactly as your healthcare provider tells you
Your healthcare provider will decide how long you stay on treatment
Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to
Take LYNPARZA by mouth 2 times a day with or without food
Each dose should be taken about 12 hours apart
Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
If you are taking LYNPARZA for early breast cancer and you have hormone receptor-positive disease, you should continue to take hormonal therapy during your treatment with LYNPARZA
If you are taking LYNPARZA for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with LYNPARZA unless you have had a surgery to remove both of your testicles (surgical castration) to lower the amount of testosterone in your body
If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?
Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
LYNPARZA may cause serious side effects (see "What is the most important information I should know about LYNPARZA?").
Nausea or vomiting is common during treatment with LYNPARZA. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms.
The most common side effects of LYNPARZA when used alone are:

tiredness or weakness
low red blood cell counts
diarrhea
loss of appetite
headache
changes in the way food tastes
cough
low white blood cell counts
shortness of breath
dizziness
indigestion or heartburn
low platelet counts

The most common side effects of LYNPARZA when used in combination with bevacizumab are:

tiredness or weakness
low red blood cell counts
diarrhea
low white blood cell counts
urinary tract infection
headache

The most common side effects of LYNPARZA when used in combination with abiraterone and prednisone or prednisolone are:

low red blood cell counts
tiredness or weakness
diarrhea
loss of appetite
low white blood cell counts
dizziness
stomach-area (abdominal) pain

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects. You may report side effects related to AstraZeneca products(Opens in new window)
[IMG: Visit AstraZeneca.com to Report Side Effects]
.
Please see complete Prescribing Information, including Medication Guide.

[H2] WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

ovarian, fallopian tube, or primary peritoneal cancer:

that is advanced and has a certain type of inherited

15000 chars

🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)

5Review mentions (all pages)

4External proof links (all pages)

Page	Reviews	Proof links
/ (home)	1	1
/ovarian-cancer/home.html	1	1
/patient-support.html	1	1
/patient-support/my-lynparza-support-program.html	2	1

🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)

Homepage schema

[
    {
        "@context": "https://schema.org/",
        "url": "https://www.lynparza.com/",
        "@type": "MedicalWebPage",
        "name": "LYNPARZA",
        "description": "Discover LYNPARZA—an oral, non-chemotherapy medication that may give you and your doctor a different option in the treatment of certain types of cancer."
    },
    {
        "@context": "https://schema.org/",
        "url": "https://www.lynparza.com/",
        "@type": "MedicalAudience",
        "audienceType": "Patient",
        "geographicArea": "For US consumers"
    },
    {
        "@context": "https://schema.org/",
        "url": "https://www.lynparza.com/",
        "@type": "Website",
        "name": "Lynparza.com"
    }
]

/ovarian-cancer/home.html

[
    {
        "@context": "https://schema.org/",
        "url": "https://www.lynparza.com/ovarian-cancer/home.html",
        "@type": "MedicalWebPage",
        "name": "Talk to your doctor about LYNPARZA for certain types of advanced or recurrent ovarian cancer.",
        "description": "LYNPARZA is used as a maintenance therapy and can be taken alone or in combination with the medicine bevacizumab. Maintenance therapy is a treatment used after initial therapy has ended. It can help extend the time without cancer growing or returning."
    },
    {
        "@context": "https://schema.org/",
        "url": "https://www.lynparza.com/ovarian-cancer/home.html",
        "@type": "MedicalAudience",
        "audienceType": "Patient",
        "geographicArea": "For US consumers"
    }
]

/patient-support.html

[
    {
        "@context": "https://schema.org/",
        "url": "https://www.lynparza.com/patient-support.html",
        "@type": "MedicalWebPage",
        "name": "Patient support",
        "description": "Access resources that are designed to guide and support you during your treatment with LYNPARZA."
    },
    {
        "@context": "https://schema.org/",
        "url": "https://www.lynparza.com/patient-support.html",
        "@type": "MedicalAudience",
        "audienceType": "Patient",
        "geographicArea": "For US consumers"
    }
]

/patient-support/my-lynparza-support-program.html

[
    {
        "@context": "https://schema.org/",
        "url": "https://www.lynparza.com/patient-support/my-lynparza-support-program.html",
        "@type": "MedicalWebPage",
        "name": "Education and support are available through MyLYNPARZA",
        "description": "AstraZeneca developed this support program to be there for you and your loved ones during treatment with LYNPARZA. By signing up, you will receive advice and information about treatment"
    },
    {
        "@context": "https://schema.org/",
        "url": "https://www.lynparza.com/patient-support/my-lynparza-support-program.html",
        "@type": "MedicalAudience",
        "audienceType": "Patient",
        "geographicArea": "For US consumers"
    }
]

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30

Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?

Semantic Coherence 0 / 20

Compare the homepage promise against the sub-page reality. Do they hold the same line?

Trust & Proof 0 / 20

Weigh review mentions against actual external proof links. Claims without verification = theatre.

Commodity Fingerprint 0 / 15

Check headings & narrative against the industry clichés in the setup above.

Identity & Authority 0 / 15

Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?

Your predicted BS score 0 / 100

💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

BS Level

Medical Devices, Pharma & Biotech

40.7 Avg BS

Based on 784 businesses audited.

✓ Less BS than average

LYNPARZA (AstraZeneca) has 15.7 points less BS than the average for Medical Devices, Pharma & Biotech.

BS Detector

Medical Devices, Pharma & Biotech BS: LYNPARZA (AstraZeneca) (lynparza.com)

https://lynparza.com 📍 Industry: Medical Devices, Pharma & Biotech

25 BS / 100

Expert Verdict

This is a high-substance, low-fluff pharmaceutical portal where every claim is constrained by legal safety requirements. It is a functional medical utility, not a marketing experiment, resulting in a very low BS score of 25.

Info Density Power-words vs. Substance ratio.

20% BS

Semantic Coherence Homepage promise vs. Sub-page reality.

10% BS

Trust & Proof Verifiable evidence vs. Trust Theatre.

40% BS

Commodity Fingerprint Detection of industry clichés/templates.

47% BS

Identity & Authority Expert verifiability & Schema depth.

13% BS

BS Reduction Prescription

Integrate specific ClinicalTrials.gov registration numbers (NCT IDs) directly into the results sections to allow for external validation. Upgrade the schema_json from generic MedicalWebPage to the more specific Drug schema to include FDA approval dates and specific molecular IDs. Provide a more verifiable digital footprint for the patient stories, perhaps via a dedicated video portal or external social proof. Reduce the structural redundancy by condensing repeated footer-level safety blocks into a single high-visibility modal.

Industry Match & Score Summary

Industry Classification

The website perfectly aligns with the Pharma and Biotech industry category. The content is heavily saturated with regulatory-required language, including Important Safety Information (ISI) and specific clinical indications for oncology medications.

“The score of 25 is primarily driven by the trust and proof pillar (8) due to the lack of external verification for patient stories and the commodity fingerprint (7) of the site's structural template. Information density and identity are extremely strong, preventing the score from rising into the moderate or high BS ranges.”

See Full BS Audit →

Analysis Disclosure & Source Attribution

This training module utilizes a snapshot of public data from LYNPARZA (AstraZeneca), captured on May 31, 2026, to demonstrate how machine logic evaluates different types of business narratives.

Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.

Notice to LYNPARZA (AstraZeneca): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.

Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.

To all users: You are encouraged to visit the live site at https://lynparza.com to view the most current version of its content and learn from the source what this company is about and what it offers.

Brand AI Reputation

Training Example: LYNPARZA (AstraZeneca) – Review the Data, Give Your Score & Compare to the Real AI Evaluation